Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q9SIU2

Entry ID Method Resolution Chain Position Source
AF-Q9SIU2-F1 Predicted AlphaFoldDB

87 variants for Q9SIU2

Variant ID(s) Position Change Description Diseaes Association Provenance
tmp_2_5637132_A_C 27 H>P No 1000Genomes
tmp_2_5637233_G_T 33 G>C No 1000Genomes
tmp_2_5637234_G_A 33 G>D No 1000Genomes
ENSVATH05437621 42 S>C No 1000Genomes
tmp_2_5637279_C_T 48 P>L No 1000Genomes
tmp_2_5637381_T_C,G 49 F>C No 1000Genomes
tmp_2_5637381_T_C,G 49 F>S No 1000Genomes
tmp_2_5637415_G_C 60 K>N No 1000Genomes
ENSVATH01764008 80 Q>L No 1000Genomes
ENSVATH05437639 87 H>Q No 1000Genomes
tmp_2_5637985_A_G 89 N>D No 1000Genomes
ENSVATH13021244 92 V>I No 1000Genomes
tmp_2_5638435_C_T 145 P>L No 1000Genomes
tmp_2_5638735_A_G 184 I>V No 1000Genomes
ENSVATH01764014 195 S>A No 1000Genomes
ENSVATH01764014 195 S>P No 1000Genomes
tmp_2_5638769_C_A 195 S>Y No 1000Genomes
ENSVATH05437654 202 F>V No 1000Genomes
ENSVATH00226367 205 G>A No 1000Genomes
ENSVATH05437663 217 V>M No 1000Genomes
ENSVATH05437664 229 S>F No 1000Genomes
tmp_2_5639300_C_G 238 P>R No 1000Genomes
ENSVATH00226372 257 R>L No 1000Genomes
ENSVATH00226373 258 P>S No 1000Genomes
ENSVATH00226374 265 P>S No 1000Genomes
tmp_2_5639399_A_T 271 H>L No 1000Genomes
tmp_2_5639402_C_T 272 S>L No 1000Genomes
ENSVATH01764018 273 R>K No 1000Genomes
ENSVATH00226375 285 T>M No 1000Genomes
ENSVATH00226376 296 I>V No 1000Genomes
ENSVATH00226378 305 V>I No 1000Genomes
tmp_2_5640297_G_A 345 E>K No 1000Genomes
ENSVATH13021282 352 L>V No 1000Genomes
ENSVATH13021298 363 P>Q No 1000Genomes
ENSVATH05437699 404 M>R No 1000Genomes
ENSVATH00226383 408 T>A No 1000Genomes
ENSVATH05437700 409 R>C No 1000Genomes
ENSVATH00226385 432 F>Y No 1000Genomes
ENSVATH14398355 459 W>G No 1000Genomes
ENSVATH13021321 467 E>Q No 1000Genomes
ENSVATH13021322 471 A>T No 1000Genomes
tmp_2_5641428_A_T 473 E>D No 1000Genomes
ENSVATH05437713 474 E>D No 1000Genomes
ENSVATH13021323 475 L>F No 1000Genomes
tmp_2_5641447_G_C 480 A>P No 1000Genomes
ENSVATH13021324 483 N>S No 1000Genomes
tmp_2_5641465_T_A 486 Y>N No 1000Genomes
tmp_2_5641503_G_T 498 Q>H No 1000Genomes
tmp_2_5641514_C_T 502 A>V No 1000Genomes
tmp_2_5641523_G_A 505 S>N No 1000Genomes
ENSVATH13021325 515 R>L No 1000Genomes
tmp_2_5641708_C_T 567 L>F No 1000Genomes
tmp_2_5641722_C_G 571 N>K No 1000Genomes
ENSVATH05437716 572 D>N No 1000Genomes
tmp_2_5641729_C_A 574 Q>K No 1000Genomes
tmp_2_5641730_A_T 574 Q>L No 1000Genomes
ENSVATH01764040 587 N>Y No 1000Genomes
ENSVATH00226387 596 I>V No 1000Genomes
ENSVATH14398357 608 Q>H No 1000Genomes
tmp_2_5641834_G_T 609 A>S No 1000Genomes
ENSVATH00226388 616 S>T No 1000Genomes
ENSVATH14398358 625 V>A No 1000Genomes
tmp_2_5642043_G_T 648 R>S No 1000Genomes
tmp_2_5642063_C_T 655 T>M No 1000Genomes
tmp_2_5642081_C_G 661 A>G No 1000Genomes
ENSVATH13021329 669 R>Q No 1000Genomes
ENSVATH13021330 670 V>A No 1000Genomes
tmp_2_5642125_G_A 676 E>K No 1000Genomes
tmp_2_5642158_G_A 687 V>I No 1000Genomes
tmp_2_5642209_A_G 704 K>E No 1000Genomes
tmp_2_5642222_C_T 708 A>V No 1000Genomes
tmp_2_5642251_G_A 718 A>T No 1000Genomes
tmp_2_5642282_C_A 728 S>Y No 1000Genomes
tmp_2_5642290_G_C 731 E>Q No 1000Genomes
tmp_2_5642382_A_T 733 L>F No 1000Genomes
tmp_2_5642414_T_G 744 V>G No 1000Genomes
ENSVATH00226396 750 P>A No 1000Genomes
tmp_2_5642438_C_T 752 P>L No 1000Genomes
ENSVATH00226398 758 V>M No 1000Genomes
ENSVATH05437722 765 G>R No 1000Genomes
tmp_2_5642514_C_G 777 D>E No 1000Genomes
ENSVATH13021331 780 N>I No 1000Genomes
ENSVATH00226400 787 C>S No 1000Genomes
ENSVATH13021332 811 A>V No 1000Genomes
ENSVATH01764052 819 E>Q No 1000Genomes
ENSVATH13021347 827 S>L No 1000Genomes
ENSVATH01764055 831 V>M No 1000Genomes

No associated diseases with Q9SIU2

3 regional properties for Q9SIU2

Type Name Position InterPro Accession
domain MIF4G-like, type 3 8 - 228 IPR003890
domain MIF4G-like, type 1 313 - 466 IPR015172
domain MIF4G-like, type 2 493 - 812 IPR015174

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
  • Cytoplasm
  • Predominantly nuclear
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

4 GO annotations of cellular component

Name Definition
mitochondrion A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.
mRNA cap binding complex Any protein complex that binds to an mRNA cap at any time in the lifetime of the mRNA.
nuclear cap binding complex A conserved heterodimeric protein complex that binds to the 5' terminal cap structure m7G(5')ppp(5')N of nascent eukaryotic RNA polymerase II transcripts such as pre-mRNA and U snRNA. The consists of proteins known as CBP20 and CBP80, binds to cap structures in the nucleus, and is involved in pre-mRNA splicing, 3'-end formation, and RNA nuclear export.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

2 GO annotations of molecular function

Name Definition
mRNA binding Binding to messenger RNA (mRNA), an intermediate molecule between DNA and protein. mRNA includes UTR and coding sequences, but does not contain introns.
RNA cap binding Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule.

14 GO annotations of biological process

Name Definition
7-methylguanosine mRNA capping Addition of the 7-methylguanosine cap to the 5' end of a nascent messenger RNA transcript.
abscisic acid-activated signaling pathway involved in stomatal movement Any abscisic acid mediated signaling pathway that is involved in stomatal movement.
alternative mRNA splicing, via spliceosome The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition.
defense response to virus Reactions triggered in response to the presence of a virus that act to protect the cell or organism.
long-day photoperiodism, flowering A change from the vegetative to the reproductive phase as a result of detection of, or exposure to, a period of light that exceeds the critical day length. The critical day length varies between species. Although the term is long-day is used, most species actually respond to the duration of the night, so that the response will occur when a period of darkness falls short of the number of hours defined by 24 minus the critical day length.
miRNA-mediated gene silencing A post-transcriptional gene silencing pathway in which regulatory microRNAs (miRNAs) elicit silencing of specific target genes. miRNAs are endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endonucleolytic cleavage of the RNA (often mRNA) or mRNA translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA. miRNAs are present in all the animals and in plants, whereas siRNAs are present in lower animals and in plants.
mRNA export from nucleus The directed movement of mRNA from the nucleus to the cytoplasm.
mRNA splicing, via spliceosome The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.
mRNA transcription by RNA polymerase II The cellular synthesis of messenger RNA (mRNA) from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter.
nuclear-transcribed mRNA catabolic process The chemical reactions and pathways resulting in the breakdown of nuclear-transcribed mRNAs in eukaryotic cells.
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay The nonsense-mediated decay pathway for nuclear-transcribed mRNAs degrades mRNAs in which an amino-acid codon has changed to a nonsense codon; this prevents the translation of such mRNAs into truncated, and potentially harmful, proteins.
primary miRNA processing A process involved in the conversion of a primary microRNA transcript into a pre-microRNA molecule.
response to abscisic acid Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an abscisic acid stimulus.
RNA splicing, via endonucleolytic cleavage and ligation Splicing of RNA via recognition of the folded RNA structure that brings the 5' and 3' splice sites into proximity and cleavage of the RNA at both the 3' and 5' splice sites by an endonucleolytic mechanism, followed by ligation of the exons.

6 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q5ZJZ6 NCBP1 Nuclear cap-binding protein subunit 1 Gallus gallus (Chicken) PR
Q7K4N3 Cbp80 Nuclear cap-binding protein subunit 1 Drosophila melanogaster (Fruit fly) PR
Q09161 NCBP1 Nuclear cap-binding protein subunit 1 Homo sapiens (Human) PR
Q3UYV9 Ncbp1 Nuclear cap-binding protein subunit 1 Mus musculus (Mouse) PR
Q56A27 Ncbp1 Nuclear cap-binding protein subunit 1 Rattus norvegicus (Rat) PR
Q6DIE2 ncbp1 Nuclear cap-binding protein subunit 1 Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) PR
10 20 30 40 50 60
MSNWKTLLLR IGEKGPEYGT SSDYKDHIET CFGVIRREIE RSGDQVLPFL LQCAEQLPHK
70 80 90 100 110 120
IPLYGTLIGL LNLENEDFVQ KLVESVHANF QVALDSGNCN SIRILLRFMT SLLCSKVIQP
130 140 150 160 170 180
ASLIVVFETL LSSAATTVDE EKGNPSWQPQ ADFYVICILS SLPWGGSELA EQVPDEIERV
190 200 210 220 230 240
LVGIQAYLSI RKNSSTSGLN FFHNGEFESS LAEKDFVEDL LDRIQSLASN GWKLESVPRP
250 260 270 280 290 300
HLSFEAQLVA GKFHELRPIK CMEQPSPPSD HSRAYSGKQK HDALTRYPQR IRRLNIFPAN
310 320 330 340 350 360
KMEDVQPIDR FVVEEYLLDV LFYLNGCRKE CASYMANLPV TFRYEYLMAE TLFSQILLLP
370 380 390 400 410 420
QPPFKTLYYT LVIMDLCKAL PGAFPAVVAG AVRALFEKIS DLDMESRTRL ILWFSHHLSN
430 440 450 460 470 480
FQFIWPWEEW AFVLDLPKWA PKRVFVQEIL QREVRLSYWD KIKQSIENAT ALEELLPPKA
490 500 510 520 530 540
GPNFMYSLEE GKEKTEEQQL SAELSRKVKE KQTARDMIVW IEETIYPVHG FEVTLTIVVQ
550 560 570 580 590 600
TLLDIGSKSF THLVTVLERY GQVFSKLCPD NDKQVMLLSQ VSTYWKNNVQ MTAVAIDRMM
610 620 630 640 650 660
GYRLVSNQAI VRWVFSPENV DQFHVSDQPW EILGNALNKT YNRISDLRKD ISNITKNVLV
670 680 690 700 710 720
AEKASANARV ELEAAESKLS LVEGEPVLGE NPAKMKRLKS TVEKTGEAEL SLRESLEAKE
730 740 750 760 770 780
ALLNRALSET EVLLLLLFQS FLGVLKERLP DPTKVRSVQD LKSIGAEDDK PSAMDVDSEN
790 800 810 820 830 840
GNPKKSCEVG EREQWCLSTL GYLTAFTRQY ASEIWPHMEK LESEVFSGED VHPLFLQAIS
SALQFPLH